5GZ.F WAVERLEY PHARMA INC.
- Market cap
- EUR 662K
- P/E
- -
- P/B
- 1.11x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 5GZ.F undervalued?
Graham numberThe Graham number of WAVERLEY PHARMA INC. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
WAVERLEY PHARMA INC. fundamental analysis
No fundamental analysis for WAVERLEY PHARMA INC. yet.
WAVERLEY PHARMA INC. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About WAVERLEY PHARMA INC.
Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops PARP-1 Inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. In addition, it is involved in the sale of prescription medications, over-the-counter products, and associated pharmacy services. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.
Full company profileWAVERLEY PHARMA INC. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
WAVERLEY PHARMA INC. annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 1.75M | 1.25M | 412K | 475K | 1.35M | 1.20M |
| Gross Profit | 223K | 284K | 79.8K | 214K | 514K | 411K |
| Operating Income | -787K | -638K | -1.23M | -744K | -349K | -441K |
| EBITDA | - | -426K | -1.72M | -656K | -131K | -254K |
| Net Income | -797K | -664K | -2.22M | -947K | -499K | -618K |
| EPS | -0.01 | -0.01 | -0.04 | -0.02 | -0.01 | -0.01 |
| Balance Sheet | ||||||
| Total Assets | 3.68M | 2.69M | 952K | 2.05M | 1.24M | 1.11M |
| Total Liabilities | 1.89M | 1.60M | 2.09M | 4.08M | 3.82M | 3.96M |
| Shareholders' Equity | 1.79M | 1.09M | -1.14M | -2.03M | -2.57M | -2.86M |
| Cash & Short-term Investments | 158K | 134K | 53.0K | 236K | 45.0K | 45.0K |
| Cash Flow | ||||||
| Operating Cash Flow | -799K | -237K | -1.02M | -410K | -611K | -294K |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -799K | -237K | -1.02M | -410K | -611K | -294K |
| Ratios | ||||||
| ROE | -44.5% | -60.9% | - | - | - | - |
| ROA | -21.6% | -24.7% | -233.5% | -46.3% | -40.1% | -55.9% |
| Net Profit Margin | -45.4% | -53.3% | -539.7% | -199.2% | -37.0% | -51.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
WAVERLEY PHARMA INC. dividends
WAVERLEY PHARMA INC. has not paid dividends in the last 5 fiscal years.
Who owns WAVERLEY PHARMA INC.
- Insiders 74.91%
- Institutions 0.00%
- Public & others 25.10%
- Shares outstanding 54.0M
- Free float 13.6M
WAVERLEY PHARMA INC. company profile
- Company name
- WAVERLEY PHARMA INC.
- Ticker
- 5GZ.F
- ISIN
- CA94357L1058
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 4-1250 Waverley Street, Winnipeg, MB, Canada, R3T 6C6
- Phone
- 204 928 7907
- Website
- waverleypharma.com
About WAVERLEY PHARMA INC.
Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops PARP-1 Inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. In addition, it is involved in the sale of prescription medications, over-the-counter products, and associated pharmacy services. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.
WAVERLEY PHARMA INC. management
2- Mr. Larry Thiessen M.B.A.President, CEO & Director
- Mr. James F. Kinley C.A., CPAInterim CFO & Director · born 1978